Program
zimberelimab
Also written as “Zimberelimab”, “GLS-010” and “AB122”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Uterine Cervical Neoplasms · Adenocarcinoma Of Esophagus · Neoplasm Metastasis · Biliary Tract Neoplasms, led by 5 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Guangzhou Gloria Biosciences | 74 open or running | phase 3since Aug 19, 2022 | Aug 28, 2018 | Dec 2026phase 2 · NCT05909436 |
| Arcus Biosciences | 60 open or running | phase 3since Oct 3, 2022 | Jul 17, 2018 | none ahead |
| Gilead Sciences | 43 open or running | phase 3since Aug 12, 2022 | Apr 26, 2018 | Jun 2028phase 3 · NCT05502237 |
| Otsuka | 22 open or running | phase 3since Jul 3, 2026 | Jul 27, 2021 | Jun 2027phase 1 · NCT04999761 |
| RemeGen | 11 open or running | phase 2since Nov 23, 2023 | Nov 23, 2023 | Jun 30, 2027phase 2 · NCT06155396 |
Also a collaborator on its studies: Merck KGaA, Darmstadt, Germany and strata-oncology.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 6 studies since Apr 26, 2018.
- Aug 29, 2019Phase 1 study in Advanced Solid TumorsArcus Biosciences · NCT04087018 · 18 enrolled · United States
- Jan 23, 2020Phase 2 study in Carcinoma, Non-Small-Cell LungArcus Biosciences · NCT04262856 · 151 enrolled · United States, Australia, Canada and more
- Jan 29, 2021Phase 2 study in Carcinoma, Non-Small-Cell LungArcus Biosciences · NCT04736173 · 169 enrolled · United States, Hong Kong, Malaysia and more
- Feb 5, 2021Phase 1 study in Advanced Solid TumorsGilead Sciences · NCT04747470 · 13 enrolled · United States
- Jul 27, 2021Otsuka's first study: phase 1 study in Neoplasm MetastasisNew to OtsukaOtsuka · NCT04999761 · 917 planned · Japan
- Aug 12, 2022Phase 3 study in Carcinoma, Non-Small-Cell LungGilead Sciences · NCT05502237 · 1,021 enrolled · United States, Argentina, Austria and more
- Aug 19, 2022Phase 3 study in RecurrenceGuangzhou Gloria Biosciences · NCT05518318 · 60 planned
- Oct 3, 2022Phase 3 study in Adenocarcinoma Of EsophagusArcus Biosciences · NCT05568095 · 1,040 enrolled · United States, Argentina, Australia and more
- Nov 21, 2022Phase 2 study in Lung NeoplasmsGilead Sciences · NCT05633667 · 192 enrolled · United States, Brazil, Hong Kong and more
- Dec 26, 2022Phase 3 study in RecurrenceGuangzhou Gloria Biosciences · NCT05798819 · 424 planned · China
- May 4, 2023Phase 2 study in Solid TumorGuangzhou Gloria Biosciences · NCT05909436 · 107 planned · China
- Jul 26, 2023Phase 2 study in Advanced Non-Small Cell Lung CancerGuangzhou Gloria Biosciences · NCT05978401 · 152 planned · China
- Nov 23, 2023RemeGen's first study: phase 2 study in Uterine Cervical NeoplasmsNew to RemeGenRemeGen · NCT06155396 · 116 planned · China
- Jul 3, 2026Phase 3 study in Biliary Tract NeoplasmsPhase 3 reachedOtsuka · NCT07710885 · 784 planned · Australia, Japan, South Korea and more
Ahead
- Dec 2026Primary completion: phase 2 study in Solid TumorGuangzhou Gloria Biosciences · NCT05909436
- Jun 2027Primary completion: phase 1 study in Neoplasm MetastasisOtsuka · NCT04999761
- Jun 30, 2027Primary completion: phase 2 study in Uterine Cervical NeoplasmsRemeGen · NCT06155396
- Jun 2028Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungGilead Sciences · NCT05502237
TargetBeta
“A human immunoglobulin G4 (IgG4) monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), ”NCIt, by rule
“Programmed cell death protein 1 inhibitor”ChEMBL 37, by rule
Other programs on PDCD1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivonescimabrule | Akeso | phase 3 | 48 |
| rilvegostomig | AstraZeneca | phase 3 | 24 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| tivunatamig | Pfizer | phase 3 | 15 |
| nilvanstomigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 15 |
| pucotenlimabrule | taizhou-hanzhong-biomedical-co-ltd | phase 3 | 15 |
| enlonstobartrule | CSPC Pharmaceutical Group | phase 3 | 15 |
| ezabenlimab | Boehringer Ingelheim | phase 3 | 13 |
| Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363rule | Innovent Biologics | phase 3 | 10 |
| rulonilimabrule | Lunan Pharmaceutical Group | phase 3 | 9 |
| Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 | Sino Biopharmaceutical | phase 3 | 4 |
Studies
All 20 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07710885Biliary Tract Neoplasms · Australia, Japan, South Korea and more | 3 | Recruiting | Otsuka | Apr 30, 2030 | 784 |
| NCT06155396Uterine Cervical Neoplasms · China | 2 | Recruiting | RemeGen | Jun 30, 2027 | 116 |
| NCT05978401Advanced Non-Small Cell Lung Cancer · China | 2 | Not yet recruiting | Guangzhou Gloria Biosciences | Apr 1, 2025 | 152 |
| NCT05909436Solid Tumor · China | 2 | Recruiting | Guangzhou Gloria Biosciences | Dec 2026 | 107 |
| NCT05798819Recurrence · China | 3 | Recruiting | Guangzhou Gloria Biosciences | Dec 31, 2029 | 424 |
| NCT05633667Lung Neoplasms · United States, Brazil, Hong Kong and more | 2 | Active, not recruiting | Gilead Sciences | Sep 2029 | 192 |
| NCT05568095Adenocarcinoma Of Esophagus · United States, Argentina, Australia and more | 3 | Completed | Arcus Biosciences | Aug 28, 2026 | 1,040 |
| NCT05518318Recurrence | 3 | Not yet recruiting | Guangzhou Gloria Biosciences | Jun 2025 | 60 |
| NCT05502237Carcinoma, Non-Small-Cell Lung · United States, Argentina, Austria and more | 3 | Active, not recruiting | Gilead Sciences | Jun 2028 | 1,021 |
| NCT04999761Neoplasm Metastasis · Japan | 1 | Recruiting | Otsuka | Jun 2027 | 917 |
| NCT04747470Advanced Solid Tumors · United States | 1 | Terminated | Gilead Sciences | Nov 7, 2022 | 13 |
| NCT04736173Carcinoma, Non-Small-Cell Lung · United States, Hong Kong, Malaysia and more | 2 | Completed | Arcus Biosciences | Sep 17, 2026 | 169 |
| NCT04262856Carcinoma, Non-Small-Cell Lung · United States, Australia, Canada and more | 2 | Completed | Arcus Biosciences | Jul 9, 2025 | 151 |
| NCT04087018Advanced Solid Tumors · United States | 1 | Completed | Arcus Biosciences | Jun 17, 2024 | 18 |
| NCT03972722Uterine Cervical Neoplasms · China | 2 | UNKNOWN | Guangzhou Gloria Biosciences | May 15, 2022 | 89 |
| NCT03846310Carcinoma, Non-Small-Cell Lung · United States, Korea, Republic of, Singapore and more | 1 | Completed | Arcus Biosciences | Nov 18, 2024 | 77 |
| NCT03713905Advanced Solid Tumors · China | 1 | Completed | Guangzhou Gloria Biosciences | Feb 28, 2022 | 293 |
| NCT03655483Classical Hodgkin's Lymphoma · China | 2 | UNKNOWN | Guangzhou Gloria Biosciences | Apr 11, 2021 | 85 |
| NCT03629756Carcinoma, Non-Small-Cell Lung · United States, Australia | 1 | Completed | Arcus Biosciences | Aug 18, 2021 | 48 |
| NCT03547973Metastatic Urothelial Cancer · United States, France, Germany and more | 2 | Active, not recruiting | Gilead Sciences | Apr 2030 | 502 |
How it is read
Names in the registry
- “Zimberelimab”, 10 entries
- “GLS-010”, 6 entries
- “AB122”, 2 entries
- “GLS-012+GLS-010”, 2 entries
- “Zimberelimab (ZIM)”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 7 studies
- Uterine Cervical Neoplasms, 2 studies
- Adenocarcinoma Of Esophagus, 1 study
- Neoplasm Metastasis, 1 study
- Biliary Tract Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.